Literature DB >> 2186373

Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells.

B Mermer1, B K Felber, M Campbell, G N Pavlakis.   

Abstract

A synthetic rev gene containing substitutions which introduced unique restriction sites but did not alter the deduced amino acid sequence was used as a vehicle to construct mutations in rev. Insertion or substitution mutations within a domain of Rev resulted in proteins able to inhibit the function of Rev protein in trans. Rev function was monitored in a cell line, HLfB, which contained a rev- mutant provirus. HLfB cells require the presence of rev for virus production, which was conveniently monitored by immunoblot detection of p24gag. Trans-dominant mutants were identified after expression in bacteria and delivery into HLfB cells by protoplast fusion. In addition, the trans-dominant phenotype was verified by expression of the mutant proteins in HLfB cells after cotransfection. These studies define a region between amino acid residues 81 and 88 of rev, in which different mutations result in proteins capable of inhibiting Rev function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186373      PMCID: PMC330680          DOI: 10.1093/nar/18.8.2037

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  40 in total

1.  Structural and functional characterization of the human immunodeficiency virus rev protein.

Authors:  A Perkins; A W Cochrane; S M Ruben; C A Rosen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

2.  High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion.

Authors:  R M Sandri-Goldin; A L Goldin; M Levine; J C Glorioso
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

3.  rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA.

Authors:  B K Felber; M Hadzopoulou-Cladaras; C Cladaras; T Copeland; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

4.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

5.  Regulation of human immunodeficiency virus env expression by the rev gene product.

Authors:  M L Hammarskjöld; J Heimer; B Hammarskjöld; I Sangwan; L Albert; D Rekosh
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Mutants of Escherichia coli with a defect in the degradation of nonsense fragments.

Authors:  A I Bukhari; D Zipser
Journal:  Nat New Biol       Date:  1973-06-20

7.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Protoplast formation in Escherichia coli.

Authors:  R L Weiss
Journal:  J Bacteriol       Date:  1976-11       Impact factor: 3.490

10.  Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus.

Authors:  A I Dayton; E F Terwilliger; J Potz; M Kowalski; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988
View more
  57 in total

1.  cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K.

Authors:  C Magin; R Löwer; J Löwer
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Rec (formerly Corf) function requires interaction with a complex, folded RNA structure within its responsive element rather than binding to a discrete specific binding site.

Authors:  C Magin-Lachmann; S Hahn; H Strobel; U Held; J Löwer; R Löwer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Identification of a domain in human immunodeficiency virus type 1 rev that is required for functional activity and modulates association with subnuclear compartments containing splicing factor SC35.

Authors:  D M D'Agostino; T Ferro; L Zotti; F Meggio; L A Pinna; L Chieco-Bianchi; V Ciminale
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  Expression of biologically active HIV glycoproteins using a T7 RNA polymerase-based eucaryotic vector system.

Authors:  T Wilk; H Mierswa; H G Kräusslich; J J Dunn; V Bosch
Journal:  Virus Genes       Date:  1992-08       Impact factor: 2.332

6.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.

Authors:  M H Malim; D F McCarn; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

8.  Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance.

Authors:  I Weichselbraun; J Berger; M Dobrovnik; H Bogerd; R Grassmann; W C Greene; J Hauber; E Böhnlein
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2.

Authors:  E D Garrett; B R Cullen
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

10.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.